|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Measurement of body composition as a surrogate evaluation of energy balance in obese patients显示文摘In clinical practice obesity is primarily diagnosed through the body mass index. In order to characterize patients affected by obesity the use of traditional anthropometric measures appears misleading. Beyond the body mass index, there are overwhelming evidences towards the relevance of a more detailed description of the individual phenotype by characterizing the main body componentsas free-fat mass, muscle mass, and fat mass. Among the numerous techniques actually available, bioelectrical impedance analysis seems to be the most suitable in a clinical setting because it is simple, inexpensive, noninvasive, and highly reproducible. To date, there is no consensus concerning the use of one preferred equation for the resting energy expenditure in overweight and/or obese population. Energy restriction alone is an effective strategy to achieve an early and significant weight loss, however it results in a reduction of both fat and lean mass therefore promoting or aggravating an unfavourable body composition(as sarcobesity) in terms of mortality and comorbidities. Therefore the implementation of daily levels of physical activity should be simultaneously promoted. The major role of muscle mass in the energy balance has been recently established by the rising prevalence of the combination of two condition as sarcopenia and obesity. Physical exercise stimulates energy expenditure, thereby directly improving energy balance, and also promotes adaptations such as fiber type, mitochondrial biogenesis, improvement of insulin resistance, and release of myokines, which may influence different tissues, including muscle. | Carlo Maria Rotella Ilaria Dicembrini | 2015 | World Journal of Methodology2015，5，1： | 8 |
| 2 | Orlistat and sibutramine beyond weight loss显示文摘 | MANNUCCI E DICEMBRINI I ROTELLA F | 2008 | Nutrition Metabolism & Cardiovascular Diseases2008，18，5： | 1 |
| 3 | Safety of dipeptidyl peptidase-4 inhibitor: a meta-analysis of randomized clinical trials显示文摘 | MONAMI M DICEMBRINI I MARTELLI D | 2011 | Curt' Med Res Opin2011，273，： | 1 |
| 4 | Dipeptidyl pepti- dase-4 inhibitors and bone fractures: a meta-analysis of rando- mized clinical trials显示文摘 | Monami M Dicembrini I Antenore A | 2011 | Diabetes Care2011，34，11： | 1 |
| 5 | Dipeptidyl peptidase‐4 inhibitors and cardiovascular risk: a meta‐analysis of randomized clinical trials显示文摘 | M. Monami B. Ahrén I. Dicembrini E. Mannucci | 2012 | Diabetes Obes Metab2012，，： | 1 |
| 6 | Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials显示文摘 | Monami M Dicembrini I Antenore A | 2011 | Diabetes Care2011，34，11： | 1 |
| 7 | Dipeptidyl peptidase-4 inhibitors and risk of cancer:myth or reality显示文摘 | MonamiM Dicembrini I Zannoni S | 2011 | European Association for the Study of Diabetes2011，16，： | 1 |
| 8 | Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures: A meta-analysis of randomized clinical trials显示文摘 | Monami Matteo Dicembrini Ilaria Antenore Alessandro Mannucci Edoardo | 2011 | Diabetes Care2011，，11： | 1 |
| 9 | Dipeptidyl peptidase-4 inhibitors and pancreatitis risk:a meta-analysis of randomized clinical trials显示文摘 | Monami M Dicembrini I Mannucci E | | 0，，01： | 1 |
| 10 | Dipeptidyl peptidase-4inhibitors and bone fractures:a meta-analysis of randomized clinical trials显示文摘 | Monami M Dicembrini I Antenore A | 2011 | Diabetes Care2011，34，11： | 1 |
| 11 | Safety of dipeptidyl peptidase-4 inhibitors:a meta-analysis of randomized clinical trials显示文摘 | Monami M Dicembrini I Martelli D | | 0，，3： | 1 |
| 12 | From Theo- ry to Clinical Practice in the Use of GLP-1 Receptor Agonists and DPP-4 Inhibitors 显示文摘 | Ilaria Dicembrini Laura Pala CarloMaria Rotella | 2011 | Therapy Experimental Diabetes Re- search2011，，： | 1 |
| 13 | Different modulation of dipeptidyl peptidase-4 activity between microvascular and macrovascular human endothelial cells显示文摘 | Pala L Pezzatini A Dicembrini I | | 0，，03： | 1 |
| 14 | Incretin-based therapies and cardiovascular risk显示文摘 | Mannucci E Dicembrini I | 2012 | Curr Med Res Opin2012，28，5： | 1 |
| 15 | Dipeptidyl peptidase-4 in-hibitors and cardiovascular risk: ameta-analysis of randomized clini-cal trials显示文摘 | Monami M Ahre n B Dicembrini I | 2012 | Diabetes Obes Metab2012，23，： | 1 |
| 16 | Dipeptidyl pepti- dase-4 inhibitors and bone fractures: a meta-analysis of ran- domized clinical trials 显示文摘 | Monami M Dicembrini I Antenore A | 2011 | Diabetes Care2011，34，11： | 1 |
| 17 | Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-a- nalysis of randomized clinical trials 显示文摘 | Monami M Ahr6n B Dicembrini I | 2013 | Diabetes Obes Metab2013，15，2： | 1 |
| 18 | Safety of dipep- tidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials显示文摘 | Monami M Dicembrini I Martelli D | 2011 | Curt Med Res Opin2011，27，： | 1 |
| 19 | Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials显示文摘 | Monami M Dicembrini I Mannueci E | 2014 | Diabetes Obesity and Metabolism2014，16，1： | 1 |
| 20 | A comparison of mealtime insulin aspart and human insulin in combination with metformin in type 2 diabetes patients显示文摘 | Pala L Mannucci E Dicembrini I | | 0，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员